Health Ministry threatens subsidies

Wylot, Robert
March 2002
Warsaw Business Journal;3/18/2002, Vol. 8 Issue 11, p4
Reports the threat of the Health Ministry to eliminate government subsidies for products unless drug importers lower prices. Pressure on foreign companies to cut prices; Percentage of income of drug makers attributed to the government; Plan of the government to reduce money refunded to pharmaceutical companies.


Related Articles

  • France Cuts Drug Subsidies. Houlton, Sarah // Pharmaceutical Executive;Jun2003, Vol. 23 Issue 6, p18 

    Reports on the decision of the France government to cut its subsidy on medicines it thinks are moderately useful. Aim to reduce the health department's budget deficit; Implications on patients; List of some of the products that will be affected by the subsidy cuts.

  • Drug supply in spotlight. Long, Jonathan; Buss, Jessica // Farmers Weekly;10/8/2004, Vol. 141 Issue 15, p30 

    Reports on the cross-subsidization of professional work with drug costs in Great Britain. Results of a survey on the amount that the average dairy client spends on fees for veterinarians; Disadvantage of sourcing drugs from a variety of outlets; Factors to consider in sustaining large animal...

  • Australian PBS announces new listings and price changes.  // PharmacoEconomics & Outcomes News;10/15/2011, Issue 639, p9 

    The article reports that medicines on the pharmaceutical benefits scheme (PBS) will be subsidize by the Australian government. The subsidy will also cover drugs that were deferred in February 2011 for fiscal reasons, but will be included in the list due to Pharmaceutical Benefits Advisory...

  • Letters. Pilon, Roger; Durfield, Amber; Foley, Jan; Krakojf, Charles // Reason;Aug/Sep2007, Vol. 39 Issue 4, p6 

    Several letters to the editor are presented in response to articles in the May 2007 issue including "Exporting Drug Prices," by Jacob Sullum, "Assault Behind Bars," by Cathy Young and "The Folly of Southern Hospitality," by John F. Sugg.

  • Subsidizing HIV/AIDS Drugs: An Overview. Farrell, Courtney; English, Marlanda // Points of View: Subsidizing HIV/AIDS Drugs;3/1/2016, p1 

    The article examines the debate over the provision of subsidies for antiretroviral drug treatment by the U.S. government. The prices of antiretroviral drugs are lower in developing countries than in the U.S. and Western Europe. Moreover, generic versions of such drugs may be produced in...

  • Differences in willingness to pay for artemisinin-based combinations or monotherapy: experiences from the United Republic of Tanzania. Wiseman, Virginia; Onwujekwe, Obinna; Matovu, Fred; Mutabingwa, Theonest K.; Whitty, Christopher J. M. // Bulletin of the World Health Organization;Nov2005, Vol. 83 Issue 11, p845 

    Objectives The cost of combination treatment is thought to be one of the greatest barriers to their deployment, but this has not been tested directly. Estimates of willingness to pay were compared across four drug combinations used to treat Tanzanian children with uncomplicated malaria. The...

  • Drug maker picks up tab for Arimidex. Cameron, Amanda // New Zealand Doctor;4/19/2006, p4 

    Reports on the decision of AstraZeneca to offer the drug Arimidex for free to postmenopausal women with hormone-sensitive breast cancer who do not meet Pharmac's criteria for full funding, in April 2006. Price of the drug; Overview of the sample program of AstraZeneca; Reason that influenced the...

  • Counterpoint: HIV/AIDS Drug Subsidies Are Ineffective. Rich, Alex K.; Konczal, Ed // Points of View: Subsidizing HIV/AIDS Drugs;3/1/2016, p3 

    The article presents an argument that spending funds on the distribution of antiretroviral drugs for AIDS patients is futile due to the complexity of the human immunodeficiency virus (HIV). It is asserted that providing subsidies for expensive AIDS drugs will not be enough to be able to reach...

  • Subsidizing HIV/AIDS Drugs: An Overview. Baskey-East, Sabrina // Canadian Points of View: Subsidizing HIV/AIDS Drugs;2016, p1 

    The article presents general information regarding the subsidization of HIV and AIDS drugs. The author reviews the cost of HIV and AIDS drug treatments and the availability of Canadian public and private drug coverage. Efforts to subsidize drug coverage for people in sub-Saharan Africa diagnosed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics